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irolimus- Versus Paclitaxel-Eluting Stents for
he Treatment of Cardiac Allograft Vasculopathy
ichael S. Lee, MD,* Giuseppe Tarantini, MD,† Jola Xhaxho, MD,† Tae Yang, MD,*
shkan Ehdaie, MD,* Ravi Bhatia, MD,* Enrico Favaretto, MD,† Jonathan Tobis, MD*
os Angeles, California; and Padua, Italy
bjectives The aim of this study was to compare outcomes after percutaneous coronary interven-
ion (PCI) with sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) in the treatment of
ardiac allograft vasculopathy (CAV).
ackground PCI in patients with CAV is associated with increased rates of restenosis compared
ith PCI in patients without CAV. There are no dedicated studies on the inﬂuence of different drug-
luting stents (DES) on the outcomes of patients with CAV.
ethods This is a retrospective observational study of 108 consecutive patients with CAV who un-
erwent PCI with SES and PES at UCLA Medical Center and University of Padova Medical Center be-
ween 2002 and 2008.
esults Baseline characteristics were similar among SES (n  68) and PES (n  40) patients with
he exception of older patients, larger minimal lumen diameter, and smaller diameter stenosis in the
ES-treated patients. Angiographic follow-up at 1 year was high in the SES and PES groups (74% vs.
6%, p  0.8). The SES and PES groups had similar binary restenosis rates (10% vs. 9%, p  0.7),
ercent diameter stenosis (24  24% vs. 24  18%, p  0.94), and late lumen loss (0.67  1.03 mm
s. 0.68  1.11 mm, p  0.9). One-year clinical outcomes were not signiﬁcantly different among
AV patients treated with either SES or PES (major adverse cardiac events: 10% vs. 15%, p  0.5;
eath: 3% vs. 5%, p  0.4; myocardial infarction: 3% vs. 5%, p  0.4; target vessel revascularization:
% vs. 8%, p  0.3).
onclusions In patients who underwent PCI for CAV, both SES and PES were safe and effective
ith no signiﬁcant differences in clinical and angiographic outcomes. Randomized clinical trials com-
aring different DES with longer follow-up are necessary to identify the optimal treatment strategy
or patients with CAV. (J Am Coll Cardiol Intv 2010;3:378–82) © 2010 by the American College of
ardiology Foundation
rom the *Division of Cardiology, UCLA Medical Center, Los Angeles, California; and the †Department of Cardiac, Thoracic,
nd Vascular Sciences, University of Padova Medical Center, Padua, Italy. Dr. Lee has served on the Speakers’ Bureau for
chering-Plough, Boston Scientific, Bristol-Myers Squibb, and Daiichi Sankyo.anuscript received February 1, 2010, accepted February 5, 2010.
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379ardiac allograft vasculopathy (CAV) is a rapidly progressive
orm of atherosclerosis that can lead to allograft loss and
ccounts for 25% of deaths between years 1 and 10 after
rthotopic heart transplantation (OHT) (1). The prevalence of
AV is 32% to 42% at 5-year follow-up (1,2). The treatment
ptions include repeat OHT, coronary artery bypass graft
urgery (CABG), or percutaneous coronary intervention
PCI), but all have their limitations. Retransplantation is less
ffective compared with the first OHT and is considered in
elect cases of severe coronary artery disease but is limited by a
aucity of donors (3). Even when it is performed, CAV can
ecur in the second graft. Coronary artery bypass graft surgery
as been performed but is associated with a perioperative
ortality rate 30% (4,5). Clinical data for CABG in CAV
re limited and outdated by over 10 years.
Percutaneous coronary intervention has been used as a
alliative treatment option for CAV but is associated with
orse clinical outcomes and higher rates of restenosis com-
ared with PCI in non-CAV lesions. Several studies reported
hat PCI with drug-eluting stents (DES) in patients with
AV was safe and reduced the rate of angiographic restenosis
ompared with bare-metal stents (BMS), but no studies have
eported on the influence between different DES on outcomes
6,7). We report the angiographic and clinical outcomes of
esions treated with sirolimus-eluting stents (SES) compared
ith paclitaxel-eluting stents (PES) in an observational study
f patients with CAV.
ethods
his is a retrospective observational study of 108 consecutive
atients with CAV who received SES (Cypher, Cordis, John-
on & Johnson Corporation, Miami, Florida) or PES (Taxus,
oston Scientific Corporation, Natick, Massachusetts) at the
niversity of California at Los Angeles (UCLA) Medical
enter and the University of Padova Medical Center, Padua,
taly, between 2002 and 2008. The institutional review board
t each institution approved the use of the database review for
his study. Thirty-nine of the 108 patients in this study were
ncluded in a previous study from UCLA Medical Center (6).
The choice of immunosuppressive therapy was at the
iscretion of the transplant cardiologist at the 2 institutions
nd included cyclosporine, prednisone, azathioprine, myco-
henolate mofetil, tacrolimus, and sirolimus.
The PCI was performed with standard techniques. The
hoice of anticoagulation and DES and the use of hemody-
amic support devices and intravascular ultrasound (Boston
cientific Corporation) were left to the operator’s discretion.
ll patients received both aspirin and clopidogrel for a mini-
um of 6 months. Intracoronary nitroglycerin was prophylac-
ically administered to decrease the risk of vasospasm.
Clinical data including baseline characteristics obtained
rom medical records and follow-up data were gathered
etrospectively and entered into a computerized cardiovas- cular database. Surveillance angiography was performed
ithin the first 12 months after PCI or earlier if clinically
ndicated. Major adverse cardiac events were defined as the
omposite of cardiac death, myocardial infarction, and
arget vessel revascularization (TVR). Myocardial infarction
as diagnosed on the basis of the presence of new Q waves
n at least 2 contiguous electrocardiographic leads and
levated cardiac enzymes including creatine kinase-MB
raction. When pathologic Q waves were absent, myocardial
nfarction was diagnosed if the creatine kinase level in-
reased to more than twice the upper limit of the normal
ange with an elevated level of creatine kinase-MB or
roponin I. Target vessel revascularization was defined as a
epeat revascularization driven by any lesion located in the
ame epicardial vessel treated at the index procedure.
The Academic Research Consortium definition of defi-
ite/confirmed stent thrombosis
s an acute coronary syndrome
ith angiographic confirmation
f stent thrombus or occlusion
r pathologic confirmation of
cute stent thrombosis. Probable
tent thrombosis is defined as
ny unexplained death within 30
ays or as target vessel myocar-
ial infarction without angio-
raphic confirmation of throm-
osis or other identified culprit
esion. Possible stent thrombosis
s defined as unexplained death
fter 30 days. Subacute stent
hrombosis is defined as stent
hrombosis occurring within 30
ays of PCI, and late stent
hrombosis occurs between 31
nd 365 days after PCI.
Quantitative coronary analysis
as performed with an auto-
ated edge detection computer analysis system (GE
A1000 Stenosis Analysis Application, GE Healthcare,
iscataway, New Jersey) in 69 patients who underwent PCI
t UCLA Medical Center and with QCA-CMS system
ersion 4.0 (MEDIS Medical Imaging Systems, Inc., Ley-
en, the Netherlands) in 39 patients who underwent PCI at
niversity of Padova Medical Center. The contrast-filled
ontapered catheter tip was used for calibration. The
arameters that were measured included the reference di-
meter of the vessel, the minimal lumen diameter (MLD),
ercent diameter stenosis (difference between the reference
iameter and MLD divided by the reference diameter and
ultiplied by 100), and late lumen loss (difference between
LD at the end of the procedure and MLD at follow-up).
Continuous variables are presented as mean  SD and
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CABG  coronary artery
bypass graft surgery
CAV  cardiac allograft
vasculopathy
DES  drug-eluting stent(s)
MLD  minimal lumen
diameter
OHT  orthotopic heart
transplantation
PCI  percutaneous
coronary intervention
PES  paclitaxel-eluting
stent(s)
SES  sirolimus-eluting
stent(s)
TVR  target vessel
revascularizationompared with the Student t test. Categorical variables are
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380resented as percentages and compared by chi-square or
isher exact tests. Statistical analysis was performed with
PSS version 10.0 (SPSS, Inc., Chicago, Illinois). A value
f p  0.05 was considered statistically significant.
esults
aseline characteristics. Of the 108 patients who underwent
CI with DES, 68 patients received SES and 40 patients
eceived PES (Table 1). The 2 groups were well-matched,
xcept patients treated with SES were older (age 61  14
ears vs. 54  19 years, p  0.03).
aseline angiographic and procedural characteristics. The
ES group had a larger MLD (0.93  0.45 mm vs. 0.67 
.34 mm, p 0.01) and a smaller diameter stenosis (66 14%
s. 76  10%, p  0.001) compared with the PES group
Table 2). The acute gain (1.53  0.53 mm vs. 1.84  0.58
m, p  0.02) was larger in the PES group. The mean stent
iameter was larger in the SES group (3.04  0.34 mm vs.
.88  0.39 mm, p  0.04) and might be explained by the
vailability of a 2.25-mm PES. The mean reference vessel
iameter, mean lesion length, final MLD, mean stent length,
nd stents used per patient were similar in the 2 cohorts.
ollow-up angiography. Table 3 shows the results of the
ngiographic follow-up. At 1 year, angiographic follow-up
as similar in both the SES and PES groups (74% vs. 76%,
 0.8). The binary restenosis rates in the SES and PES
Table 1. Baseline Clinical Characteristics
SES
(n  68)
PES
(n  40) p Value
Age (yrs) 61 14 54 19 0.03
Male 47 (69) 28 (70) 0.7
Hypertension 49 (72) 24 (60) 0.3
Hypercholesterolemia 41 (60) 21 (53) 0.5
Diabetes 17 (25) 13 (33) 0.54
Chronic renal insufﬁciency 36 (53) 20 (50) 0.7
Mean ejection fraction (%) 58 14 57 13 0.73
Yrs post-OHT (%) 10 4 10 5 0.55
Clinical presentation
Elective 57 (84) 37 (92) 0.28
UA/NSTEMI 10 (15) 2 (5) 0.21
STEMI 7 (1) 1 (3) 0.7
Immunosuppressive therapy
Cyclosporin 43 (63) 17 (43) 0.68
Azathioprine 10 (15) 4 (10) 0.57
Mycophenolate 22 (33) 16 (40) 0.56
Prednisone 34 (50) 17 (43) 0.53
Sirolimus 19 (28) 17 (43) 0.18
Tacrolimus 15 (22) 15 (38) 0.13
Values are mean SD or n (%).
NSTEMI  non–ST-segment elevation myocardial infarction; OHT  orthotopic heart
transplantation; PES  paclitaxel-eluting stent(s); SES  sirolimus-eluting stent(s); STEMI ST-segment elevation myocardial infarction; UA unstable angina.roups were low (10% vs. 9%, p  0.7). The SES and PES
roups had similar percent diameter stenosis (24  24% vs.
4  18%, p  0.9) and late lumen loss (0.67  1.03 mm
s. 0.68  1.11 mm, p  0.9).
ne-year clinical outcomes. No significant differences were
bserved in major adverse cardiac events between the SES
nd PES groups (10% vs. 15%, p  0.5) (Table 4). No
ignificant differences in cardiac death (3% vs. 5%, p  0.4)
nd myocardial infarction (3% vs. 5%, p  0.4) were
bserved in the 2 groups. The SES and PES groups had low
ates of TVR (4% vs. 8%, p  0.3) and target lesion
evascularization (3% vs. 3%, p  0.9). No patients under-
ent repeat OHT.
tent thrombosis. There was no significant difference in
tent thrombosis between the SES and PES groups (1.5%
s. 5.0%, p  0.3). Subacute stent thrombosis occurred in 1
atient who received an SES who died suddenly on day 7.
ate stent thrombosis occurred on day 282 in 1 patient who
eceived a PES and discontinued dual antiplatelet therapy
efore colonoscopy without the knowledge of his cardiolo-
Table 3. 1-Year Angiographic Outcomes
SES
(n  68)
PES
(n  40) p Value
Follow-up angiography 50 (74) 30 (76) 0.8
Binary restenosis 7 (10) 4 (9) 0.7
Percent diameter stenosis 24 24 24 18 0.9
Late lumen loss (mm) 0.67 1.03 0.68 1.11 0.9
MLD (mm) 2.25 0.78 2.31 0.70 0.8
Values are n (%) or mean SD.
Table 2. Angiographic and Procedural Characteristics
SES
(n  68)
PES
(n  40) p Value
Mean RVD (mm) 2.84 0.60 3.03 1.32 0.4
MLD (mm) 0.93 0.45 0.67 0.34 0.01
Diameter stenosis (%) 66 14 76 10 0.001
Mean lesion length (mm) 14.9 7.2 15.0 6.2 0.9
Lesion type
A 18 (26) 13 (32) 0.3
B1/B2 40 (59) 21 (53) 0.5
C 25 (37) 13 (32) 0.6
Mean stent diameter (mm) 3.04 0.34 2.88 0.39 0.04
Mean stent length (mm) 22 13 21 9 0.5
Final MLD (mm) 2.48 0.42 2.51 0.50 0.8
Stents/patient 1.41 0.85 1.20 0.41 0.14
Acute gain (mm) 1.53 0.53 1.84 0.58 0.02
IVUS use 5 (7) 6 (15) 0.34
IABP use 3 (4) 2 (5) 0.74
Values are mean SD or n (%).
IABP  intra-aortic balloon pump; IVUS  intravascular ultrasound; MLD  minimal lumen
diameter; RVD reference vessel diameter.Abbreviations as in Tables 1 and 2.
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381ist. He subsequently died from cardiogenic and septic
hock. A 17-year-old female subject who was noncompliant
ith medication died suddenly 155 days after PCI with
ES.
iscussion
he main findings of the first head-to-head comparison of
DES for the management of CAV are that the rates of
inary restenosis and TVR were low and not significantly
ifferent at 1-year follow-up. There were also no significant
ifferences in the rates of death, myocardial infarction, and
tent thrombosis.
Cardiac allograft vasculopathy continues to represent the
ost common cause of late graft failure (8). The patho-
hysiology of CAV is different from native coronary disease
n that it is characterized by diffuse intimal hyperplasia in
he epicardial arteries and microcirculation (9–11). The
rogression to CAV seems to be multifactorial and associ-
ted with immunologic factors (Human Leukocyte Antigen
onor/recipient mismatches, recurrent cellular rejection,
nd antibody-mediated rejection), nonimmunologic factors
hyperlipidemia, hypertension, diabetes mellitus, and hyper-
omocysteinemia), and donor-related factors (older donor
ge and donor brain death) (12–14). Cytomegalovirus
nfection even in asymptomatic patients is associated with
ore frequent CAV (8). Patients with humoral rejection
ave a 10% and 36% greater incidence of CAV at 1 and 5
ears, respectively (15).
In addition to aggressive control of cardiac risk factors,
CI is an essential treatment strategy for patients with CAV
8). Although PCI might be beneficial in treating CAV for
ocal lesions, the diffuse nature of CAV can make it difficult
o treat. The late lumen loss and binary restenosis observed
n our SES patients (0.67 1.03 mm and 10%, respectively)
ere higher than that reported in patients with native
oronary artery lesions in the SIRIUS (Sirolimus-Eluting
tent in de Novo Native Coronary Lesions) trial (0.17 
.45 mm and 3.2%, respectively) (6). Similarly, the late
Table 4. 1-Year Clinical Outcomes
SES
(n  68)
PES
(n  40) p Value
Major adverse cardiac events 7 (10) 6 (15) 0.5
Cardiac death 2 (3) 2 (5) 0.4
Myocardial infarction 2 (3) 2 (5) 0.4
Target vessel revascularization 3 (4) 3 (8) 0.3
Target lesion revascularization 2 (3) 1 (3) 0.9
Stent thrombosis 1 (1.5) 2 (5) 0.3
Repeat transplantation 0 (0) 0 (0) 0.9
Values are n (%).
Abbreviations as in Table 1.umen loss and binary restenosis in our PES patients (0.68 o1.11 mm and 9%, respectively) was higher than that
eported in patients in the TAXUS IV trial (Boston
cientific) (0.39  0.50 mm and 5.5%, respectively) (17).
he pro-inflammatory state of CAV leading to accelerated
roliferation of the intima, media, and adventitia might help
xplain why restenosis rates and late lumen loss are higher in
AV patients compared with patients with native coronary
rtery disease.
The limited data thus far have shown that SES and PES
ight decrease the rate of restenosis in CAV patients
ompared with BMS. At a mean follow-up of 1 year, when
ompared with BMS, SES and PES were associated with a
ower binary restenosis rate (12% vs. 30%, p  0.02) (6).
imilarly, a study from Columbia University reported that
ES and PES had less in-stent restenosis (18.6%) compared
ith BMS (49%) for the treatment of CAV (7).
The SES and PES significantly reduce the rate of
estenosis and subsequent need for repeat revascularization
ompared with BMS in native coronary arteries (16–18). A
eta-analysis of 16 randomized trials reported that, com-
ared with PES, SES was associated with a lower rate of
arget lesion revascularization (hazard ratio: 0.74, 95%
onfidence interval: 0.63 to 0.87) and lower rate of stent
hrombosis (hazard ratio: 0.66, 95% confidence interval:
.46 to 0.94) without a significant difference in the com-
osite end point of death or myocardial infarction (19).
owever, SES and PES have not been previously compared
or the treatment of CAV. Our analysis revealed that both
ES and PES performed well with no significant difference
n the rates of restenosis and TVR within the first year.
The long-term safety of DES in patients with CAV is
nknown. There were no significant differences between
ES and PES in terms of cardiac death (3% vs. 5%, p 0.4)
nd myocardial infarction (3% vs. 5%, p  0.4) at 1 year.
tent thrombosis might be underdiagnosed in OHT pa-
ients, because it does not always manifest in typical symp-
oms like chest pain due to denervation of the allografted
eart. Stent thrombosis occurred in 2 patients with PES and
rematurely discontinued dual antiplatelet therapy. Prema-
ure discontinuation was identified as the strongest inde-
endent predictor of stent thrombosis (20). Only 1 patient
ho was taking dual antiplatelet therapy experienced prob-
ble stent thrombosis. The difference in the rate of stent
hrombosis was not statistically significant (1.5% vs. 5%,
 0.3), but our study was not powered to detect a
ifference in this clinically important end point.
Sirolimus is an immunosuppressant with more utility
han in the use of intracoronary stents. One study showed
hat, when OHT patients were switched from calcineurin
nhibitors to sirolimus, there was attenuation in the progres-
ion of CAV (21). In nontransplant patients, the OSIRIS (Oral
irolimus to Inhibit Recurrent In-stent Stenosis) trial
howed that high-dose sirolimus prevented the recurrence
f angiographic restenosis for the treatment of in-stent
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382estenosis (22). In our study, the administration of oral
irolimus as the immunosuppressant was lower in the SES
roup (28% vs. 43%, p  0.18), and this might have been a
onfounding variable in our study. Future studies comparing
he use of oral sirolimus in combination with DES in CAV
ould be interesting.
A limitation of this study was the study design. A retro-
pective, nonrandomized study has its cost-effectiveness yet
as some drawbacks. Because selection bias was unavoid-
ble, we were not able to appropriately adjust for treatment
ffect. The study was also limited by the small number of
atients in each group. Although the results indicate no
ignificant difference between the 2 types of stents in the
etting of CAV, our study was not powered to detect a true
ifference. Because there are limited data in PCI of CAV, a
arge centralized database would be useful to detect possible
mall differences that might exist. There were significant
ngiographic and procedural differences between the 2
roups. The follow-up was only 1 year, and thus the
ong-term outcomes are unknown in patients with CAV
ho undergo PCI with DES. Follow-up angiography was
ot performed on all patients who underwent PCI. Two
ifferent computer analysis systems were used to perform
uantitative coronary analysis at the institutions.
onclusions
n the largest study of DES in CAV patients, there were no
ignificant differences in angiographic and clinical outcomes
etween SES and PES at 1 year. Both stents seem to be safe
nd effective and seem to be good options for the treatment
f CAV. Randomized clinical trials with appropriate sample
ize comparing different DES with longer follow-up are
ecessary to identify the optimal treatment strategy for
atients with CAV.
eprint requests and correspondence: Dr. Michael S. Lee,
CLA Medical Center, 10833 Le Conte Avenue, Room A2-237
HS, Los Angeles, California 90095. E-mail: mslee@mednet
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